Oppenheimer lowered the firm’s price target on Vertex Pharmaceuticals (VRTX) to $540 from $550 and keeps an Outperform rating on the shares ahead of quarterly results. The firm is updating its model with script data and adjustments, driving the new price target
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VRTX:
- Vertex Pharmaceuticals price target raised to $562 from $477 at UBS
- Disney initiated, Cisco upgraded: Wall Street’s top analyst calls
- Vertex Pharmaceuticals initiated with a Sector Perform at Scotiabank
- Vertex Pharmaceuticals price target lowered to $541 from $550 at BofA
- Vertex Pharmaceuticals reinstated with a Market Perform at Raymond James